The CDC's Vaccine Panel Decision: A Concern for Hepatitis B Prevention
The recent decision by the US Centers for Disease Control and Prevention (CDC) vaccine panel to discontinue the Hepatitis B vaccine recommendation for newborns has sparked debate among experts. Dr. Ben Kasstan-Dabush, an Assistant Professor at the London School of Hygiene & Tropical Medicine (LSHTM), offers an insightful perspective on this development.
A Routine Update or a Strategic Shift?
Dr. Kasstan-Dabush clarifies that updates to routine immunisation schedules are common, often driven by risk assessments, epidemiological data, and cost-benefit analyses. For instance, England recently revised its schedule, removing the Hib-MenC vaccine. However, he expresses concern about the US context.
"The situation in the U.S. is different," he says. "The Advisory Committee on Immunization Practices (ACIP) underwent a significant change earlier this year, with members critical of vaccines taking their place. This shift raises questions about the decision-making process behind the Hepatitis B vaccine recommendation."
Potential Implications for Public Confidence
Dr. Kasstan-Dabush highlights a potential consequence of this decision: "My concern is that this move could be part of a broader strategy to gradually reduce the routine vaccination schedule and erode public trust in immunisation in the United States."
This development invites further exploration of the relationship between vaccine policy, public health, and trust. The discussion around the Hepatitis B vaccine recommendation serves as a reminder of the ongoing need for evidence-based decision-making in public health.
For more information, visit the BBC article: https://www.bbc.co.uk/news/articles/cwypwznx9kqo
Declaration of Interests:
Dr. Ben Kasstan-Dabush confirms that he has no competing interests to disclose.
